|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cilostazol#Warnings]] |
| {{Cilostazol}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ==Warnings And Precautions==
| |
| {|
| |
| |<div style="background: WhiteSmoke; float: left; text-align: left; padding: 1em;">
| |
| '''''Cilostazol (PLETAL) and several of its metabolites are inhibitors of [[phosphodiesterase]] III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV [[congestive heart failure]]. PLETAL is contraindicated in patients with congestive heart failure of any severity.PLETAL is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding [[peptic ulcer]] and intracranial bleeding. PLETAL inhibits platelet aggregation in a reversible manner. PLETAL is contraindicated in patients with known or suspected [[hypersensitivity]] to any of its components<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>'''''
| |
| </div>
| |
| |}<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PLETAL (CILOSTAZOL) TABLET [OTSUKA AMERICA PHARMACEUTICAL, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=24d75b58-bafb-4440-b8d7-4f4079c08b0b | publisher = | date = | accessdate = }}</ref>
| |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |